Shenzhen Hepalink Reports Q1 Profit Amid Financial Challenges
Shenzhen Hepalink Pharmaceutical Group Co Ltd reported a profit of 0.11 HKD per share for Q1 2025, marking a positive development for the company after facing financial challenges.
- Shenzhen Hepalink Pharmaceutical Group Co Ltd
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read